Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here
Thursday, May 24, 2012
Sanofi to test cancer-starving compound in China in 2013
The compound, called slit-trap, was developed by its Chinese collaborator, Shanghai Institutes of Biological Sciences, and will soon be ready for a "first-in-man" trial.